Michael Gold

Summary

Affiliation: GlaxoSmithKline Research and Development
Country: USA

Publications

  1. ncbi Study design factors and patient demographics and their effect on the decline of placebo-treated subjects in randomized clinical trials in Alzheimer's disease
    Michael Gold
    GlaxoSmithKline, Research Triangle Park, NC 27709, USA
    J Clin Psychiatry 68:430-8. 2007
  2. pmc Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study
    Michael Gold
    Neurosciences Medicines Development Center, GlaxoSmithKline, Stockley Park, Harlow, UK
    Dement Geriatr Cogn Disord 30:131-46. 2010
  3. doi Predictors of placebo response in pooled lamotrigine neuropathic pain clinical trials
    Michael C Irizarry
    WW Epidemiology, GlaxoSmithKline, Research Triangle Park, NC, USA
    Clin J Pain 25:469-76. 2009
  4. doi SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study
    Gareth Maher-Edwards
    GlaxoSmithKline, Uxbridge, Middlesex, UK
    Int J Geriatr Psychiatry 26:536-44. 2011
  5. ncbi Rationale and design of a randomized controlled trial to assess the safety and efficacy of cardiac resynchronization therapy in patients with asymptomatic left ventricular dysfunction with previous symptoms or mild heart failure--the REsynchronization reV
    Cecilia Linde
    Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden
    Am Heart J 151:288-94. 2006
  6. ncbi Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease
    Henry Brodaty
    University of New South Wales, Sydney, Australia
    Dement Geriatr Cogn Disord 20:120-32. 2005
  7. ncbi Clinical safety and efficacy studies of a novel formulation combining 1.2% clindamycin phosphate and 0.025% tretinoin for the treatment of acne vulgaris
    Joel Schlessinger
    Advanced Skin Research Center, Omaha, NE, USA
    J Drugs Dermatol 6:607-15. 2007
  8. ncbi Tau therapeutics for Alzheimer's disease: the promise and the challenges
    Michael Gold
    Global Clinical Research and Development, CNS Analgesia, Johnson and Johnson Pharmaceutical Research and Development, Titusville, NJ 08560, USA
    J Mol Neurosci 19:331-4. 2002
  9. ncbi Overview of the Alliance for Cellular Signaling
    Alfred G Gilman
    Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA
    Nature 420:703-6. 2002
  10. ncbi Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank
    Warren W Barker
    Wien Center for Alzheimer s Disease and Memory Disorders, Mount Sinai Medical Center, Miami Beach, FL 33140, USA
    Alzheimer Dis Assoc Disord 16:203-12. 2002

Collaborators

  • Gary Landreth
  • H Brodaty
  • David Loewenstein
  • Gilberto R Sambrano
  • Suzanne Craft
  • M C Irizarry
  • William T Abraham
  • Cecilia Linde
  • Gareth Maher-Edwards
  • Joel Schlessinger
  • Warren W Barker
  • Alfred G Gilman
  • Pauline Williams
  • Jackie Hunter
  • Ruth Dixon
  • Gillian Hopton
  • Jo Hunter
  • Gemma Jacobs
  • James Leyden
  • Alan Menter
  • R Todd Plott
  • Lawrence Eichenfield
  • Craig Leonardi
  • Mitchell Wortzman
  • Pavlina Ivanova
  • Patrick J Casey
  • Nancy O'Rourke
  • Richard H Scheuermann
  • Pat Jimison
  • Ira Goodman
  • Won Do Heo
  • Deirdre Brekken
  • Bruce A Harris
  • Jason G Cyster
  • Madhusudan Natarajan
  • Bayard Miller
  • Paul C Simpson
  • Donald Hilgemann
  • Mercy Luis
  • Martin A Schmidt
  • Douglas Newland
  • Michael J Berridge
  • Jen Liou
  • Iain Fraser
  • Rochelle Long
  • Eric N Olson
  • Eugene Shepherd
  • Temple F Smith
  • Tony Hunter
  • Dianne DeCamp
  • Heping Han
  • Peter N Devreotes
  • Ronald Taussig
  • Kenneth Heilman
  • Martha L Gray
  • Mary Verghese
  • David Fruman
  • Melanie H Cobb
  • Mehmet Toner
  • Tobias Meyer
  • Robert Hsueh
  • Jeffrey S Forrester
  • Tamara Roach
  • Adam P Arkin
  • Anthony J Pawson
  • Shankar Subramaniam
  • Henry R Bourne
  • James E Ferrell
  • Pamela Eversole-Cire
  • John Doyle
  • Keng Mean Lin
  • Paul C Sternweis
  • Brian Saunders
  • Stephen B Milne
  • Melvin I Simon
  • Yingming Zhao
  • Rama Ranganathan
  • Paul W Sternberg
  • Dennis Mock
  • Alice Kashuba
  • H Alex Brown
  • James T Stull
  • Hongjun Shu
  • Yan Ni
  • Bruce Robinson
  • Marc C Mumby
  • Elliott M Ross
  • Harold Varmus
  • Robert J Lefkowitz
  • Robert S Sinkovits

Detail Information

Publications10

  1. ncbi Study design factors and patient demographics and their effect on the decline of placebo-treated subjects in randomized clinical trials in Alzheimer's disease
    Michael Gold
    GlaxoSmithKline, Research Triangle Park, NC 27709, USA
    J Clin Psychiatry 68:430-8. 2007
    ..To gain insight into factors affecting the rate of decline in placebo-treated subjects participating in Alzheimer's disease (AD) clinical trials...
  2. pmc Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study
    Michael Gold
    Neurosciences Medicines Development Center, GlaxoSmithKline, Stockley Park, Harlow, UK
    Dement Geriatr Cogn Disord 30:131-46. 2010
    ..An open-label extension study assessed the long-term safety and tolerability of 8 mg RSG XR...
  3. doi Predictors of placebo response in pooled lamotrigine neuropathic pain clinical trials
    Michael C Irizarry
    WW Epidemiology, GlaxoSmithKline, Research Triangle Park, NC, USA
    Clin J Pain 25:469-76. 2009
    ..The 574 patients in the pooled lamotrigine treatment arms were used as a replication dataset...
  4. doi SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study
    Gareth Maher-Edwards
    GlaxoSmithKline, Uxbridge, Middlesex, UK
    Int J Geriatr Psychiatry 26:536-44. 2011
    ..To estimate the treatment effects of SB-742457 and donepezil in Alzheimer disease (AD) in a contemporary clinical trial...
  5. ncbi Rationale and design of a randomized controlled trial to assess the safety and efficacy of cardiac resynchronization therapy in patients with asymptomatic left ventricular dysfunction with previous symptoms or mild heart failure--the REsynchronization reV
    Cecilia Linde
    Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden
    Am Heart J 151:288-94. 2006
    ..The effects of CRT on HF outcomes in patients with asymptomatic left ventricular dysfunction (ALVD) or mild HF remain to be determined...
  6. ncbi Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease
    Henry Brodaty
    University of New South Wales, Sydney, Australia
    Dement Geriatr Cogn Disord 20:120-32. 2005
    ....
  7. ncbi Clinical safety and efficacy studies of a novel formulation combining 1.2% clindamycin phosphate and 0.025% tretinoin for the treatment of acne vulgaris
    Joel Schlessinger
    Advanced Skin Research Center, Omaha, NE, USA
    J Drugs Dermatol 6:607-15. 2007
    ..Individual ingredients and the combination were well-tolerated. Among those treated with the combination formulation, discontinuation rates due to adverse events were 1% or less...
  8. ncbi Tau therapeutics for Alzheimer's disease: the promise and the challenges
    Michael Gold
    Global Clinical Research and Development, CNS Analgesia, Johnson and Johnson Pharmaceutical Research and Development, Titusville, NJ 08560, USA
    J Mol Neurosci 19:331-4. 2002
    ..The issues discussed in this article are not exhaustively dealt with in either scope or detail...
  9. ncbi Overview of the Alliance for Cellular Signaling
    Alfred G Gilman
    Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA
    Nature 420:703-6. 2002
    ..One goal is to catalyse complementary research in individual laboratories; to facilitate this, all alliance data are freely available for use by the entire research community...
  10. ncbi Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank
    Warren W Barker
    Wien Center for Alzheimer s Disease and Memory Disorders, Mount Sinai Medical Center, Miami Beach, FL 33140, USA
    Alzheimer Dis Assoc Disord 16:203-12. 2002
    ..These estimates of the a priori probabilities of dementing disorders have implications for clinicians and researchers...